Matthew R Lippmann1, Ami B Bhatt2. 1. Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA. mlippmann@bwh.harvard.edu. 2. Division of Cardiology, Massachusetts General Hospital, 55 Fruit St., Boston, MA, 02114, USA.
Abstract
PURPOSE OF REVIEW: There are over a million adults living with congenital heart disease (CHD) in the USA. There have been improvements in CHD management which have led to an expansion of the adult congenital heart disease (ACHD) population. There is a high prevalence of atherosclerotic cardiovascular disease (ASCVD) encountered in the aging ACHD population. This review focuses on the most recent literature regarding the primary prevention of ASCVD in young ACHD patients. RECENT FINDINGS: There are unique considerations for ASCVD risk reduction in ACHD patients. ASCVD may be as prevalent in ACHD compared in the general population. However, there may be a perceived shorter life expectancy in ACHD patients; therefore, primary prevention of ASCVD may not be considered important. Preventative strategies for ASCVD are underutilized in ACHD patients. As these patients are followed for a lifetime by cardiologists, we can truly pursue primary prevention in this aging population.
PURPOSE OF REVIEW: There are over a million adults living with congenital heart disease (CHD) in the USA. There have been improvements in CHD management which have led to an expansion of the adult congenital heart disease (ACHD) population. There is a high prevalence of atherosclerotic cardiovascular disease (ASCVD) encountered in the aging ACHD population. This review focuses on the most recent literature regarding the primary prevention of ASCVD in young ACHD patients. RECENT FINDINGS: There are unique considerations for ASCVD risk reduction in ACHD patients. ASCVD may be as prevalent in ACHD compared in the general population. However, there may be a perceived shorter life expectancy in ACHD patients; therefore, primary prevention of ASCVD may not be considered important. Preventative strategies for ASCVD are underutilized in ACHD patients. As these patients are followed for a lifetime by cardiologists, we can truly pursue primary prevention in this aging population.
Authors: Scott M Grundy; Neil J Stone; Alison L Bailey; Craig Beam; Kim K Birtcher; Roger S Blumenthal; Lynne T Braun; Sarah de Ferranti; Joseph Faiella-Tommasino; Daniel E Forman; Ronald Goldberg; Paul A Heidenreich; Mark A Hlatky; Daniel W Jones; Donald Lloyd-Jones; Nuria Lopez-Pajares; Chiadi E Ndumele; Carl E Orringer; Carmen A Peralta; Joseph J Saseen; Sidney C Smith; Laurence Sperling; Salim S Virani; Joseph Yeboah Journal: Circulation Date: 2018-11-10 Impact factor: 29.690
Authors: Morgan L Brown; Harold M Burkhart; Heidi M Connolly; Joseph A Dearani; Frank Cetta; Zhuo Li; William C Oliver; Carole A Warnes; Hartzell V Schaff Journal: J Am Coll Cardiol Date: 2013-07-10 Impact factor: 24.094
Authors: Laura D Flannery; Akl C Fahed; Doreen DeFaria Yeh; Mohamed A Youniss; Gregory L Barinsky; Ada C Stefanescu Schmidt; Oscar J Benavidez; James B Meigs; Ami B Bhatt Journal: Am J Cardiol Date: 2017-11-23 Impact factor: 2.778
Authors: Werner Budts; Guido E Pieles; Jolien W Roos-Hesselink; Maria Sanz de la Garza; Flavio D'Ascenzi; George Giannakoulas; Jan Müller; Renate Oberhoffer; Doris Ehringer-Schetitska; Vesna Herceg-Cavrak; Harald Gabriel; Domenico Corrado; Frank van Buuren; Josef Niebauer; Mats Börjesson; Stefano Caselli; Peter Fritsch; Antonio Pelliccia; Hein Heidbuchel; Sanjay Sharma; A Graham Stuart; Michael Papadakis Journal: Eur Heart J Date: 2020-11-14 Impact factor: 29.983
Authors: Donna K Arnett; Roger S Blumenthal; Michelle A Albert; Andrew B Buroker; Zachary D Goldberger; Ellen J Hahn; Cheryl Dennison Himmelfarb; Amit Khera; Donald Lloyd-Jones; J William McEvoy; Erin D Michos; Michael D Miedema; Daniel Muñoz; Sidney C Smith; Salim S Virani; Kim A Williams; Joseph Yeboah; Boback Ziaeian Journal: J Am Coll Cardiol Date: 2019-03-17 Impact factor: 24.094